Tandem Diabetes Care, Inc. announced a partnership with Juvenile Diabetes Research Foundation International Inc. (JDRF) to develop a first-of-its-kind, dual-chamber infusion pump for the management of diabetes. The partnership agreement is designed to accelerate the development of a next-generation, fully automated artificial pancreas system using therapies in conjunction with insulin. JDRF will support Tandem in performance-based milestone funding over the next two years to complete the development, testing, and manufacturing of a novel infusion pump that can simultaneously deliver two injectable hormonal drug therapies.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
46.99 USD | -0.66% |
|
+9.33% | +58.86% |
01/07 | Tandem Diabetes Care, Inc.(NasdaqGM:TNDM) dropped from Russell Small Cap Comp Value Index | CI |
01/07 | Tandem Diabetes Care, Inc.(NasdaqGM:TNDM) dropped from Russell Midcap Growth Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+58.86% | 305.51Cr | |
-6.68% | 18TCr | |
-5.20% | 9.88TCr | |
-5.38% | 6.53TCr | |
+17.99% | 4.54TCr | |
-6.47% | 4.49TCr | |
+9.74% | 4.38TCr | |
+14.01% | 2.9TCr | |
+21.29% | 2.56TCr | |
-6.53% | 2.33TCr |
- Stock Market
- Equities
- TNDM Stock
- News Tandem Diabetes Care, Inc.
- Tandem Diabetes Care, Inc. Announces Partnership with Juvenile Diabetes Research Foundation International Inc. to Develop Dual-Chamber Infusion Pump